A new tool for the assessment of satisfaction with iron chelation therapy (ICT-Sat) for patients with ß-thalassemia major

被引:8
|
作者
Elalfy, Mohsen S. [1 ]
Massoud, Walid [2 ]
Elsherif, Nayera H. [1 ]
Labib, Jonair H. [1 ]
Elalfy, Omar M. [1 ]
Elaasar, Safaa [3 ]
von Mackensen, Sylvia [4 ]
机构
[1] Ain Shams Univ, Pediat Thalassemia Ctr, Cairo, Egypt
[2] Amer Univ Cairo, Educ Testing & Assessment Div, Cairo, Egypt
[3] Ain Shams Univ, Dept Psychol, Fac Women, Cairo, Egypt
[4] Univ Med Ctr Hamburg Eppendorf UKE, Inst & Policlin Med Psychol Hamburg, Hamburg, Germany
关键词
adherence; ICT-Sat; iron chelators; patient-rated outcome; questionnaire; Thalassemia; QUALITY-OF-LIFE; BETA-THALASSEMIA; CARDIAC IRON; DESFERRIOXAMINE TREATMENT; OVERLOADED PATIENTS; DEFERASIROX; DEFERIPRONE; TRANSFUSION; DEFEROXAMINE; EFFICACY;
D O I
10.1002/pbc.23413
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background High satisfaction with iron chelation is a major determinant for adherence to ICT in beta-thalassaemia major (beta-TM) patients. In this study, a new tool to assess different domains of satisfaction for available forms of ICT was developed and validated. The impact of patients' satisfaction with ICT has been tested. Methods. Items were generated via focus groups and a preliminary version with 24 items (ICT-Sat) with an additional item for treatment preference and a knowledge questionnaire (KQ) was developed. 170 beta-TM patients from three Thalassaemia centers in Egypt, aged 2-32 years received three questionnaires to fill in; the new ICT-Sat, a KQ, and a previously validated tool for satisfaction with ICT (SICT) and retested 4-6 weeks later to ensure re-test reliability. Type of chelation, drug related adverse events, compliance with ICT, and serum ferritin level (SF) during the year prior to the study as well as available cardiac T2*data were recorded. Results. One hundred and fifty two beta-TM patients completed all questionnaires; median age was 12 years. The final 15 remaining ICT-Sat items, yielding to four domain scores, explained 70.6% of the total variance. The "perceived effectiveness" and "fear and worries" domains of the ICT-Sat correlated significantly with the domains "perceived effectiveness" and "acceptance" of the SICT. Patients treated with oral ICT were more satisfied with perceived effectiveness, and their side effects. Conclusions. A new clinically based ICT-Sat tool was developed and revealed good psychometric characteristics. Adherence to ICT was better correlated with "perceived effectiveness" and SF level. Pediatr Blood Cancer 2012; 58: 910-915. (C) 2012 Wiley Periodicals, Inc.
引用
收藏
页码:910 / 915
页数:6
相关论文
共 50 条
  • [1] Iron chelation therapy in thalassemia major
    Guven, sirin
    Erdogan, Makbule
    MEDICAL JOURNAL OF BAKIRKOY, 2007, 3 (04) : 125 - 129
  • [2] In search of the optimal iron chelation therapy for patients with thalassemia major
    Berdoukas, Vasilios
    Wood, John
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (01): : 5 - 8
  • [3] A Correlation Study Between Iron Overload, Chelation Therapy (ICT), and Metabolic Outcomes in β-Thalassemia Major (β-TDT) Patients
    De Sanctis, Vincenzo
    Soliman, Ashraf
    Daar, Shahina
    Campisi, Saveria
    Tzoulis, Ploutarchos
    HORMONE RESEARCH IN PAEDIATRICS, 2024, 97 : 423 - 423
  • [4] IRON-CHELATION THERAPY WITH ORAL DEFERIPRONE IN PATIENTS WITH THALASSEMIA MAJOR
    OLIVIERI, NF
    BRITTENHAM, GM
    MATSUI, D
    BERKOVITCH, M
    BLENDIS, LM
    CAMERON, RG
    MCCLELLAND, RA
    LIU, PP
    TEMPLETON, DM
    KOREN, G
    NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (14): : 918 - 922
  • [5] Iron-chelation therapy with oral chelators in patients with thalassemia major
    Uygun, Vedat
    Kurtoglu, Erdal
    HEMATOLOGY, 2013, 18 (01) : 50 - 55
  • [6] EARLY IRON CHELATION-THERAPY IN THALASSEMIA MAJOR
    RUSSO, G
    ROMEO, MA
    MUSUMECI, S
    SCHILIRO, G
    DIGREGORIO, F
    HAEMATOLOGICA, 1983, 68 (01) : 69 - 73
  • [7] Prospective changes of pancreatic iron in patients with thalassemia major and association with chelation therapy
    Meloni, Antonella
    Pistoia, Laura
    Ricchi, Paolo
    Allo, Massimo
    Rosso, Rosamaria
    Cuccia, Liana
    Casini, Tommaso
    Cecinati, Valerio
    Serra, Marilena
    Rossi, Vincenza
    Righi, Riccardo
    Renne, Stefania
    Vallone, Antonino
    Positano, Vincenzo
    Cademartiri, Filippo
    BLOOD ADVANCES, 2023, 7 (10) : 2237 - 2240
  • [8] EVALUATION OF IRON CHELATION THERAPY IN β-THALASSEMIA MAJOR PATIENTS IN EAST DELTA OF EGYPT
    Hassan, T.
    Badr, M.
    Hesham, M.
    Badawy, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 701 - 701
  • [9] Iron Chelation Therapy and Mobilization of Hematopoietic Peripheral Progenitors in Patients with β-Thalassemia Major
    Forni, Gian Luca
    Podesta, Marina
    Musso, Marco
    Piaggio, Giovanna
    Musallam, Khaled M.
    Balocco, Manuela
    Pozzi, Sarah
    Frassoni, Francesco
    BLOOD, 2012, 120 (21)
  • [10] The Zinc and Copper Levels in Thalassemia Major Patients, Receiving Iron Chelation Therapy
    Zekavat, Omid R.
    Bahmanjahromi, Ayda
    Haghpanah, Sezaneh
    Ebrahimi, Sara
    Cohan, Nader
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2018, 40 (03) : 178 - 181